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Leptin administration improves skeletal muscle insulin
responsiveness in diet-induced insulin-resistant rats
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Leptin administration improves skeletal muscle insulin re-
sponsiveness in diet-induced insulin-resistant rats. Am J
Physiol Endocrinol Metab 280: E130–E142, 2001.—In addi-
tion to suppressing appetite, leptin may also modulate insu-
lin secretion and action. Leptin was administered here to
insulin-resistant rats to determine its effects on secreta-
gogue-stimulated insulin release, whole body glucose dis-
posal, and insulin-stimulated skeletal muscle glucose uptake
and transport. Male Wistar rats were fed either a normal
(Con) or a high-fat (HF) diet for 3 or 6 mo. HF rats were then
treated with either vehicle (HF), leptin (HF-Lep, 10
mgzkg
21zday
21 sc), or food restriction (HF-FR) for 12–15
days. Glucose tolerance and skeletal muscle glucose uptake
and transport were signiﬁcantly impaired in HF compared
with Con. Whole body glucose tolerance and rates of insulin-
stimulated skeletal muscle glucose uptake and transport in
HF-Lep were similar to those of Con and greater than those
of HF and HF-FR. The insulin secretory response to either
glucose or tolbutamide (a pancreatic b-cell secretagogue) was
not signiﬁcantly diminished in HF-Lep. Total and plasma
membrane skeletal muscle GLUT-4 protein concentrations
were similar in Con and HF-Lep and greater than those in
HF and HF-FR. The ﬁndings suggest that chronic leptin
administration reversed a high-fat diet-induced insulin-re-
sistant state, without compromising insulin secretion.
ob gene product; high-fat diet; glucose tolerance; glucose
uptake and transport; GLUT-4 protein
LEPTIN, THE PRODUCT of the ob gene (62), has received a
great deal of attention since its discovery in 1994, due
to the ability of this 16-kDa protein hormone to reduce
visceral adipose deposition (21, 37). This biological
activity is important from a public health perspective,
as increases in visceral fat have been associated with
“insulin resistance syndrome” or Syndrome X (39).
Attenuation of insulin resistance will decrease the in-
cidence of metabolic abnormalities such as hypertri-
glyceridemia, reduced high-density lipoproteins, ele-
vated apolipoprotein B levels, and hypertension.
Furthermore, reduced visceral fat deposition may also
prevent the development of non-insulin-dependent di-
abetes (17).
It is believed that leptin exerts its primary effect by
acting on receptors in the hypothalamus, possibly via
inhibition of neuropeptide Y release (47). However,
leptin receptor isoforms are expressed in tissues other
than the hypothalamus (12, 29, 51), and insulin action
(e.g., phosphatidylinositol 3-kinase activity, skeletal
muscle glucose uptake and transport) is improved in
these tissues after leptin treatment (3, 56, 57, 60).
Improvements in insulin-stimulated glucose disposal
after chronic leptin administration were initially dem-
onstrated by Barzilai et al. (3) and Sivitz et al. (44).
Barzilai et al. (3) reported that 8 days of leptin treat-
ment increased whole body glucose uptake in Sprague-
Dawley rats as assessed by the euglycemic clamp tech-
nique. In an extension to these ﬁndings, we (60) found
that 14 days of leptin administration increased skele-
tal muscle glucose uptake and 3-O-methyl-D-glucose
(3-MG) transport in hindlimbs of Sprague-Dawley rats.
However, these observations (3, 44, 60) were made in
non-insulin-resistant animals. Although interventions
that improve carbohydrate metabolism in normal
animals also tend to be effective in insulin-resistant
animals, it is unknown whether chronic leptin admin-
istration will improve an insulin-resistant state. More-
over, ex vivo pancreatic perfusion data suggest the
possibility that leptin may have a detrimental effect on
pancreatic secretagogue responsiveness (38).
Therefore, the aims of the present investigation were
to evaluate the impact of chronic leptin administration
in an insulin-resistant rodent model by assessing 1) the
insulin secretory response to glucose and tolbutamide;
2) whole body glucose clearance; 3) insulin-stimulated
skeletal muscle glucose uptake and 3-MG transport;
and 4) if improvements in leptin-treated insulin-resis-
tant skeletal muscle result from alterations in enzy-
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METHODS
Animals. All experimental procedures were approved by
the Institutional Animal Care and Use Committees at Am-
gen (Thousand Oaks, CA) and California State University
Northridge and conformed to the guidelines for use of labo-
ratory animals published by the United States Department
of Health and Human Resources.
Eight-week-old male Wistar rats (Harlan Sprague-Daw-
ley, San Diego, CA) were housed two per cage in a tempera-
ture-, humidity-, and light-controlled room (lights on at 0630,
lights off at 1830). Rats were provided water and one of two
puriﬁed powdered diets ad libitum for 3 (experimental proto-
cols 1 and 3)o r6( experimental protocol 2) mo. The two diets
were of either normal fat content (control diet, 17% fat-
derived calories, no. 112386; Dyets, Bethlehem, PA) or high-
fat content (high-fat diet, 59% fat-derived calories, no.
112387; Dyets). Protein and carbohydrate contents of the
diets were, respectively, 20 and 63% for control and 15 and
26% for the high-fat diet. The diets were identical with
respect to vitamin and mineral content. A similar high-fat
diet has previously been shown to induce skeletal muscle
insulin resistance in rats (48, 49). Diets were stored at 4°C,
and fresh diet was provided to all rats two times a week.
At the end of the 3- or 6-mo dietary lead in, glucose
tolerance of the rats was assessed after an intraperitoneal
glucose challenge [intraperitoneal glucose tolerance test
(IPGTT)]. Rats were fasted in the morning (food out at 0900)
for 4 h before testing. At the onset of the IPGTT, rats
(nonanesthetized) were introduced to plastic restrainers and
were bled by producing a small incision in the tail vein and
milking the tail (;0.5 ml blood). After this time 0 sample was
collected, rats were injected with glucose (2 g/kg ip), and
blood was collected from the tail (;0.2 ml blood) at 30 and 90
min after injection. Blood glucose levels were determined on
all samples using a One-Touch Meter (Lifescan, San Carlos,
CA). Glucose-intolerant rats were deﬁned as those that dis-
played a blood glucose value at 90 min that was 80% or more
of the value at 30 min. With the use of this criterion, between
25 and 35% of the high fat-fed rats were found to be glucose
intolerant. Serum insulin levels in the time 0 samples were
determined by RIA (Linco Research, St. Louis, MO). Serum
leptin levels in the time 0 sample were determined by en-
zyme-linked immunosorbent assay (59).
Glucose-intolerant high-fat diet-fed rats were then assigned
to one of three treatment groups. Treatments were given for
12–15 days, during which time rats continued to consume the
high-fat diet. Two treatment groups [high-fat-fed rats (HF) and
high-fat-fed food-restricted rats (HF-FR)] received twice daily
subcutaneous injections of vehicle (PBS). The third treatment
group [high-fat-fed leptin-treated rats (HF-Lep)] was injected
subcutaneously twice daily with recombinant murine leptin (5
mgzkg
21zinjection
21,1 0m g zkg
21zday
21 total dose; Amgen).
The HF and HF-Lep groups consumed the high-fat diet ad
libitum, whereas the food-restricted (HF-FR) group was pro-
vided 15 g/day of the high-fat diet for treatment days 1–6 and 13
g/day of high-fat diet from days 7–15 of the experimental period.
These food intake values were based on observations of food
intake in the HF-Lep rats (Davis and Levin, unpublished ob-
servations). A fourth treatment group consisted of rats that had
been fed the control diet (Con) and demonstrated normal glu-
cose tolerance. Con rats continued to consume the control diet
ad libitum during the treatment periods and were injected two
times daily with PBS subcutaneously. Injections were admin-
istered at 0800 and 1800 using a volume of ;0.25 ml.
Experimental protocol 1. For this protocol, rats were main-
tained on either the control or the high-fat diet for 3 mo
before selection of glucose-intolerant rats. Glucose-intoler-
ant, high-fat-fed rats were divided into treatment groups
(n 5 10–12/group) and received either vehicle (HF) or leptin
(HF-Lep) for 15 days. An additional group of glucose-intoler-
ant, high-fat-fed rats was treated with vehicle and were food
restricted (HF-FR) following the predetermined schedule de-
scribed above that mimicked the intake of the HF-Lep rats. A
group of rats fed the control (Con) diet (n 5 10) and injected
with vehicle was also studied. Treatments were initiated
immediately after the 3-mo dietary lead in. On day 7 of the
15-day treatment period, rats were anesthetized with pento-
barbital sodium and implanted with carotid artery and jug-
ular vein cannulas. Cannulas were exteriorized in the mid-
scapular region, and patency was maintained by daily
ﬂushing with a heparin-saline solution. The insulin secretory
response to an intravenous glucose challenge (1 g/kg) was
assessed over a 60-min period on treatment day 12 in con-
scious rats. The insulin secretory response to an intravenous
tolbutamide injection (0.1 g/kg) was assessed over a 60-min
period on treatment day 14 or 15 in conscious rats. Tolbut-
amide was employed to assess pancreatic insulin secretory
capacity without the confound of glucose-sensing ability. Tol-
butamide binds to the sulfonylurea receptor in the b-cells of
the pancreas, blocking the ATP-dependent potassium (KATP)
channels and resulting in insulin secretion. For these tests,
rats were fasted in the morning (food removed at 0900) for 4 h
before and during testing. Fifteen minutes before testing, the
cannulas were extended with additional tubing (PE-50) to
allow for dosing and sampling without disturbing the rat,
and a prestudy blood sample (;0.5 ml) was drawn from the
arterial cannulas. At time 0, a small (,0.1 ml) blood sample
was drawn from the arterial cannulas, and then the test
substance was administered through the venous cannulas.
Small (,0.1 ml) blood samples were collected from the arte-
rial cannulas after glucose or tolbutamide dosing at 1.5, 3,
4.5, 6, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, and 60 min.
Serum from these samples was separated by centrifugation
and stored at 220°C until subsequent determination of glu-
cose (by the glucose oxidase method) and insulin (by RIA)
levels.
Experimental protocol 2. For this protocol, rats were main-
tained on the high-fat diet for 6 mo before selection of glu-
cose-intolerant rats. Treatment groups included HF-Lep and
HF-FR, and treatments were initiated immediately after the
6-mo dietary lead in. Glucose-intolerant, high-fat-fed rats
were divided into treatment groups (n 5 5–6/group) and
received either vehicle or leptin (HF-Lep) for 12 days. The
vehicle-treated rats were food restricted (HF-FR) following
the predetermined schedule described above that mimicked
the intake of the HF-Lep rats. As in experiment protocol 1,
rats were outﬁtted with carotid artery and jugular vein
cannulas on day 7 of treatment, and cannula patency was
ensured by daily ﬂushing with heparin-saline.
On treatment day 12, rats were fasted in the morning for
4 h before initiation of the hyperinsulinemic-euglycemic
clamp study, as previously described by Shi et al. (43). The
jugular vein cannulas were used for infusion of insulin and
glucose via serial T-shaped needle connectors. Constant in-
sulin infusion (4 mUzkg
21zmin
21) began at 0 min, and an
exogenous glucose infusion (30%) was given at variable rates
to achieve and maintain stable euglycemia. Carotid arterial
samples were taken at timed intervals, and plasma was
collected in ice-chilled microtubes containing EGTA/aproti-
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Analyzer II (Beckman Instruments, Fullerton, CA). The
packed blood cells were resuspended in heparinized saline
and reinfused.
Experimental protocol 3. For this protocol, rats were main-
tained on either the control or the high-fat diet for 3 mo
before selection of glucose-intolerant rats. Approximately
2–3 wk after the dietary lead in, animals were divided among
two perfusion groups. Perfusion group 1 consisted Con (n 5
7), HF (n 5 7), HF-FR (n 5 7), and HF-Lep (n 5 7)
animals. Perfusion group 2 consisted of Con (n 5 8), HF
(n 5 8), and HF-Lep (n 5 8) animals. Animals were treated
with either leptin or vehicle for 12 days. After the 12-day
treatment period, animals were anesthetized with an intra-
peritoneal injection of pentobarbital sodium (6.5 mg/100 g
body wt) and surgically prepared for hindlimb perfusion as
described previously by Ruderman et al. (41) and modiﬁed by
Ivy et al. (25). After the surgical preparation, the soleus (Sol),
plantaris (Plant), and red (RG) and white (WG) portions of
the gastrocnemius and quadricep were excised from the left
leg, clamp-frozen in liquid nitrogen, and stored at 280°C
until analysis. Total GLUT-4 protein concentration, enzy-
matic analysis, and muscle glycogen content were assessed in
the Sol, Plant, RG, and WG from perfusion group 1. Total
GLUT-4 protein concentration and intramuscular triglycer-
ide content was assessed in the quadriceps of perfusion group
2. The right iliac artery was then catheterized to the tip of the
femoral artery to limit perfusate ﬂow to the right hindlimb.
Catheterization of the lower abdominal vena cava to the tip
of the iliac vein permitted the collection of efﬂuent perfusate.
Immediately after catheterization of the vessels, rats were
killed via an intracardiac injection of pentobarbital sodium
as the hindlimbs were being washed out with 10 ml of
Krebs-Heinseleit buffer (KHB). The catheters were then
placed in line with a nonrecirculating perfusion system, and
the hindlimb was allowed to stabilize during a 5-min wash-
out period. The perfusate was gassed continuously with a
mixture of 95% O2–5% CO2 and was warmed to 37°C. Per-
fusate ﬂow rate was set at 5 ml/min during the 5-min stabi-
lization and the subsequent perfusion, during which the
rates of muscle glucose uptake and glucose transport were
determined.
Perfusions were carried out in the presence of a submaxi-
mal insulin concentration (500 mU/ml) for all experimental
groups. The basic perfusate medium consisted of 30% washed
time-expired human erythrocytes (HemaCare, Van Nuys,
CA), KHB (pH 7.4), 4% dialyzed BSA (Fraction V; Fisher
Scientiﬁc, Fair Lawn, NJ), and 0.2 mM pyruvate. Over the
ﬁrst 20 min, 8 mM glucose was present in the perfusate, and
it was during this period that glucose uptake was measured
across the hindlimb. Subsequent to the determination of
glucose uptake, the hindlimb was washed out with glucose-
free perfusate for 1 min in preparation for the measurement
of glucose transport. Glucose transport was measured over
an 8-min period using an 8 mM concentration of the nonme-
tabolizable glucose analog 3-MG (32 mCi 3-[
3H]MG/mmol)
and 2 mM mannitol (60 mCi D-[1-
14C]mannitol/mmol). Imme-
diately at the end of the transport period, the Sol, Plant, RG,
and WG were excised from the right leg, blotted on gauze
dampened in cold KHB, and clamp-frozen in tongs cooled in
liquid N2. The muscles were stored at 280°C until analyzed.
Sol, Plant, RG, and WG from perfusion group 1 were used to
determine rates of insulin-stimulated 3-MG transport,
whereas the quadriceps from perfusion group 2 were used to
assess insulin-stimulated plasma membrane GLUT-4 pro-
tein concentration.
Glucose uptake was determined over a 20-min nonrecircu-
lating perfusion by collecting arterial perfusate samples be-
fore perfusion and collecting the total venous efﬂuent. Well-
mixed aliquots of the arterial perfusate and venous efﬂuent
were analyzed for glucose concentration by a glucose oxidase
method on a model 2300 STAT Plus glucose analyzer (Yellow
Springs Instruments, Yellow Springs, OH). Muscle glucose
uptake, expressed in micromoles per gram per hour, was
calculated from the arteriovenous difference, the perfusate
ﬂow rate, and the weight of the muscle perfused. The weight
of the perfused muscle was determined by dissection of the
rat hindlimb (42).
Muscle samples were weighed, homogenized in 1 ml of 10%
TCA at 4°C, and centrifuged in a microcentrifuge (Fisher
Scientiﬁc, Houston, TX) for 10 min. Duplicate 300-ml samples
of the supernatant were transferred to 7-ml scintillation vials
containing 6 ml of Bio-Safe II scintillation counting cocktail
(Research Products International, Mount Prospect, IL) and
vortexed. For determination of perfusate speciﬁc activity, 200
ml of the arterial perfusate were added to 800 ml of 10% TCA
and treated the same as the muscle homogenates. The sam-
ples were counted for radioactivity in a LS 1801 liquid scin-
tillation spectrophotometer (Beckman Instruments, Fuller-
ton, CA) set for simultaneous counting of
14C/
3H. The
accumulation of intracellular 3-[
3H]MG, which is indicative
of muscle glucose transport, was calculated by subtracting
the concentration of 3-[
3H]MG in the extracellular space from
the total muscle 3-[
3H]MG concentration. The 3-[
3H]MG in
the extracellular space was quantiﬁed by measuring the
concentration of [
14C]mannitol in the homogenate.
Total skeletal muscle GLUT-4 glucose transporter content
was determined by Western blotting as described previously
(61). Brieﬂy, portions of the freeze-clamped muscles from the
left hindlimb were weighed frozen and then homogenized in
Hepes-EDTA-sucrose (HES) buffer. The protein concentra-
tion of the homogenate was determined by the Bradford (6)
method. A 100-ml sample of the tissue homogenate was di-
luted 1:1 with Laemmli (31) sample buffer. An aliquot of the
diluted homogenate sample containing 75 mg of protein was
subjected to SDS-PAGE run under reducing conditions on a
12.5% resolving gel on a Mini-Protean II dual slab cell (Bio-
Rad, Richmond, CA). Resolved proteins were transferred to
polyvinylidene diﬂuoride (PVDF) sheets (Bio-Rad, Richmond,
CA) by the method of Towbin et al. (53) using a Bio-Rad wet
transfer unit. The membranes were incubated with an afﬁn-
ity-puriﬁed polyclonal GLUT-4 antibody (donated by Dr.
Samuel W. Cushman, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda, MD) followed by
incubation with horseradish peroxidase-labeled protein A
(Amersham Life Science, Arlington Heights, IL). Antibody
binding was visualized using enhanced chemiluminescence
autoradiography in accordance with the manufacturer’s in-
structions (Amersham Life Science). Labeled bands were
quantiﬁed by capturing images of the autoradiographs in a
Macintosh G3 computer. The captured images of the autora-
diographs were produced by an image scanner (ScanJet 4C;
Hewlett Packard, Boise, ID) equipped with a transparency
module. The captured images were digitized and imported
into the public domain NIH image program (developed at the
United States National Institutes of Health and available on
the Internet at http://rsb.info.nih.gov/nih-image/). The den-
sity of the labeled bands was calculated, corrected for back-
ground activity, and expressed as a percentage of a standard
(30 mg of heart homogenate protein) run on each gel.
Plasma membrane fractions were prepared from portions
of the perfused quadricep according to the procedure of Tur-
cotte et al. (54). Brieﬂy, a portion of the quadriceps was
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7.5) that contained 0.1 mmol/l phenylmethylsulfonyl ﬂuoride,
10 mmol/l EGTA, and 10 mg/ml trypsin inhibitor, and ho-
mogenized with a PT 2100 Polytron homogenizer (Kine-
matica, Littau/Luzern, Switzerland). The homogenate was
ﬁltered and centrifuged at 100,000 g for 1 h using a Sorvall
T-1250 rotor (Kendro Laboratory Products, Newton, CT). The
pellet was resuspended in 10 mM Tris-15% sucrose buffer,
and a small aliquot from this resuspension was collected and
retained for analysis and will be referred to as the crude
homogenate. The remaining crude homogenate suspension
was layered on continuous sucrose gradients (35–70%) and
centrifuged at 120,000 g f o r2hi naSorvall Surespin 630/36
rotor. The plasma membrane layer was collected, washed in
10 mM Tris buffer, and centrifuged for1ha t100,000 g in a
Sorvall T-1250 rotor. The ﬁnal plasma membrane pellet was
resuspended in a small volume of 10 mM Tris buffer (200 ml/g
of original tissue), frozen in liquid nitrogen, and stored at
280°C until analyzed. To assess the purity of the plasma
membrane fractions, protein content of the plasma mem-
brane (6) and activity of the plasma membrane marker en-
zyme 59-nucleotidase was measured (52) and compared with
activity in the crude homogenate fraction. Aliquots of the
plasma membrane (70 mg of protein) were treated with Lae-
mmli sample buffer and subjected to SDS-PAGE run under
reducing conditions on a 10% resolving gel. Resolved proteins
were transferred to PVDF by the method of Towbin et al. (53)
using a Bio-Rad semidry transfer unit, and GLUT-4 protein
content of the plasma membrane was determined by Western
blotting as described above.
Aliquots of muscle samples that were homogenized 1:20 in
HES buffer were used for enzymatic analysis. Hexokinase,
an enzyme required for glucose metabolism, was measured
as described by Uyeda and Racker (55). Citrate synthase, a
marker of the tricarboxylic acid cycle, was measured spectro-
photometrically (45) after dilution of the initial homogenate
1:10 in 1 M TriszHCl 1 0.4% Triton X (pH 8.1). For determi-
nation of b-hydroxyacetyl-CoA dehydrogenase (b-OAC), a
marker of b-oxidation, homogenates from the WG were di-
luted 1:5, whereas homogenates from the Sol, Plant, and RG
were diluted 1:20 in 167 mM triethanolamine-HCl buffer, pH
7.0. b-OAC activity was determined spectrophotometrically
according to the procedure described by Bass et al. (4).
Muscle glycogen concentration was determined in the Sol,
Plant, RG, and WG using a modiﬁcation of the Passonneau
and Lauderdale (36) procedure. Approximately 50 mg of
muscle were dissolved in 1 ml of 1 N KOH at 70°C for 30 min.
One hundred microliters of the dissolved homogenate were
removed and neutralized with 250 ml of 0.3 M sodium acetate
buffer (pH 4.8) and 10 ml of 50% glacial acetic acid. The
homogenate was then incubated for 2 h at 100°C after the
addition of 200 ml of 2 N HCl. After the incubation, the
reaction mixture was neutralized with 2 N NaOH. Samples
were then analyzed by measuring glucosyl units by the
Trinder reaction (Sigma, St. Louis, MO). A portion of the
quadricep was homogenized 1:20 in 25 mM KF/20 mM EDTA
buffer, pH 7.0, and subjected to lipid extraction as described
by Burton et al. (9). Total triglyceride content of the lipid
extract was determined using a commercially available kit
(Inﬁnity Triglycerides; Sigma-Aldrich, St. Louis, MO).
Statistical analysis. A one-way ANOVA was used on all
variables in experimental protocols 1 and 3 to determine
whether signiﬁcant differences existed between the Con,
HF-Lep, HF, and HF-FR groups. When a signiﬁcant F-ratio
was obtained, a Fisher’s protected least signiﬁcant difference
post hoc test was employed to identify statistically signiﬁcant
differences (P , 0.05) among the means. Glucose infusion
data in experimental protocol 2 were analyzed using a two-
way ANOVA (treatment 3 time) for repeated measures.
RESULTS
Effects of high-fat diet consumption. Rats that had
consumed the high-fat diet ad libitum for 12 wk (exper-
imental protocols 1 and 3) gained signiﬁcantly more
weight and had higher fasting serum leptin concentra-
tions than did rats that consumed the control diet for
the same duration (Table 1). At the end of the 12 wk of
dietary manipulation, an IPGTT was performed to
determine which rats had developed glucose intoler-
ance as a consequence of consumption of the high-fat
diet. Results from the IPGTT of rats used in experimen-
tal protocol 3 are depicted in Fig. 1. Similar ﬁndings
were observed in the two independent cohorts of rats
used in experimental protocols 1 and 2 (data not
shown). In one of the three cohorts (Fig. 1), fasting
blood glucose levels immediately before the intraperi-
toneal glucose injection were slightly but signiﬁcantly
greater in the high-fat-fed rats compared with the
controls.
Experimental protocol 1. On treatment day 12, imme-
diately before intravenous glucose tolerance testing, a
blood sample was drawn to determine fasting hormone
and clinical chemistry of the rats. As expected, serum
leptin levels (sampled 4–6 h after the morning injec-
tion of leptin) were signiﬁcantly increased in the HF-
Lep group compared with all other groups (Table 2).
Although HF-Lep and HF-FR rats had consumed sig-
niﬁcantly less food than HF rats over the 12-day treat-
ment period, the body weights of these animals were
not signiﬁcantly less than the HF rats fed ad libitum
Table 1. Baseline prestudy body mass and hormone levels
Experimental Protocol 1
Experimental
Protocol 2 Experimental Protocol 3
Con
(n 5 10)
HF
(n 5 35) HF (n 5 13)
Con
(n 5 15)
HF
(n 5 37)
Body mass, g
2 Months old 22264 22462 24364 255612 26768
After dietary lead in 587618 644610* 769623 598615 713617*
Fasting serum insulin, ng/ml 3.560.3 2.960.2 3.360.4 3.760.8 4.060.3
Fasting serum leptin, ng/ml 10.160.8 15.161.1* ND 12.861.4 24.062.1*
Values are means 6 SE; n, no. of animals. Con, control diet; HF, high-fat diet. After dietary lead in, animals were 5 mo old in protocols
1 and 3 and 8 mo old in protocol 2. *Signiﬁcantly different from Con within experimental protocol (P , 0.05). ND, not determined.
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cantly and similarly reduced in the HF-Lep and HF-FR
groups relative to the HF group. Fasting b-hydroxybu-
tyrate levels in the HF-Lep group were signiﬁcantly
higher than all other groups. The signiﬁcant reduction
in nonesteriﬁed fatty acid levels in the HF group,
relative to the Con group, was not observed in HF-FR
or HF-Lep rats.
Intravenous glucose tolerance tests were performed
on day 12 of the treatment period. The areas under the
curve (AUCs) for glucose, calculated from 0 to 25 min
(intravenous glucose administration at 0 min), are
shown in Fig. 2A. The glucose AUC in HF rats was
signiﬁcantly increased when compared with Con rats
(P , 0.05). This increase was reversed by leptin treat-
ment in the HF-Lep rats to an AUC similar to that
observed in the Con rats and signiﬁcantly lower than
the HF rats (P , 0.01). The glucose AUC for HF-FR
rats was not different from that observed for HF rats.
AUCs for insulin, calculated from 0 to 25 min (intra-
venous glucose administration at 0 min), are shown in
Fig. 2B. The insulin secretory response to the intrave-
nous glucose challenge was not signiﬁcantly different
across the four treatments groups. There was a ten-
dency for the insulin AUC to be lowest in the HF-Lep
group. Importantly, no worsening of glucose tolerance
was observed in the HF-Lep rats, as they displayed
glucose AUCs signiﬁcantly lower than those observed
in HF rats (Fig. 2A). Leptin treatment therefore did not
signiﬁcantly affect insulin secretory output and was
accompanied by improved glucose tolerance in the in-
sulin-resistant model. Further observations of the ef-
Fig. 1. Blood glucose levels during intra-
peritoneal glucose tolerance test (IPGTT)
in rats fed either a control diet (Con, n 5
8) or a high-fat diet (HF, n 5 24) for 12
wk before testing. Values are means 6 SE.
*Signiﬁcantly different from Con (P ,
0.05).
Table 2. Body mass, food intake, serum hormones, and clinical chemistry
after 12 days of treatment/feeding regimen
Con
(n 5 10)
HF-Lep
(n 5 12)
HF
(n 5 11)
HF-FR
(n 5 12)
Body mass, g 584620 616616 645620 610620
Cumulative food intake, g 215.667.4 137.568.0*† 165.268.5* 143.264.8*†
Insulin, ng/ml 2.260.2 1.460.3 1.860.2 1.760.2
Leptin, ng/ml 6.360.9 193.5642.2† 7.561.2 5.760.9
Glucose, mg/dl 15766 14463 15267 14865
Cholesterol, mg/dl 94647 9 638 3 648 7 612
Triglycerides, mg/dl 127614 86612 107615 132633
Total protein, g/dl 6.560.1 6.360.1 6.460.2 6.560.1
Albumin, g/dl 4.060.1 3.960.1 4.260.1 4.060.1
Alanine aminotransferase, U/l 20633 1 653 4 642 8 65
Thyroxine, mg/dl 4.360.5 3.460.5† 4.960.3 3.360.3†
b-Hydroxybutyrate, mg/dl 2.260.4 6.460.6*† 3.660.5 3.860.6
Nonesteriﬁed fatty acids, meq/l 4.160.4 2.860.3 2.460.4* 3.260.4
Values are means 6 SE; n, no. of animals. HF-Lep, high-fat diet and leptin treated; HF-FR, high-fat diet and food restricted. *Signiﬁcantly
different from Con (P , 0.05). †Signiﬁcantly different from HF (P , 0.05).
E134 SKELETAL MUSCLE INSULIN RESISTANCE AND LEPTINfects of chronic leptin administration on glucose ho-
meostasis were pursued in experimental protocols 2
and 3.
To better characterize the insulin secretory capacity
after chronic leptin administration, rats from each of
the treatment groups described above underwent an
intravenous tolbutamide tolerance test on treatment
day 14 or 15. The AUCs for insulin, calculated from 0 to
60 min (intravenous tolbutamide administration at 0
min), are shown in Fig. 2C. The insulin secretory re-
sponse to the intravenous tolbutamide challenge was
similar across the four treatments groups. Again, there
was a tendency for the insulin AUC to be lower in the
HF-Lep group and in the case of tolbutamide treat-
ment was also slightly reduced in the HF-FR group.
Experimental protocol 2. The glucose infusion rates
necessary to maintain euglycemia (111 6 2 mg/dl for
HF-FR, 115 6 2 mg/dl for HF-Lep) during hyperinsu-
linemia are shown in Fig. 3. There was a signiﬁcant
increase in the glucose infusion rate for the HF-Lep
rats compared with HF-FR rats, indicating that
chronic leptin treatment of glucose-intolerant rats re-
sulted in an increase in the insulin-mediated glucose
clearance rate.
Experimental protocol 3. At day 0 of the experimen-
tal treatment period, body mass of the HF-Lep, HF,
and HF-FR groups were similar, but all high-fat diet
animals were signiﬁcantly heavier than the Con ani-
mals (Table 3). After the 12-day treatment period, body
mass of the HF-Lep and HF-FR animals was reduced
compared with day 0. However, at day 12, the body
mass of the HF-Lep, HF, and HF-FR animals remained
greater than that of the Con group.
Sol mass was similar among the high-fat diet groups
and among the Con, HF, and HF-FR groups (Table 3),
although the mass of the Sol in the HF-Lep animals
was heavier compared with Con animals. Plant mass
was similar between the HF-Lep and HF animals, but
Plant muscles of both groups were signiﬁcantly heavier
compared with Con animals (Table 3). HF animals
were also found to have Plant muscles that were
heavier than the HF-FR animals. Epididymal fat pad
mass was similar among the HF-Lep, HF, and HF-FR
groups (Table 3). Con animals had signiﬁcantly lighter
epididymal fat pads compared with the HF-Lep, HF,
and HF-FR groups.
The rates of submaximal insulin-stimulated skeletal
muscle glucose uptake were reduced by ;48 and 25%
in the HF and HF-FR animals, respectively, when
compared with the Con group (Fig. 4). In contrast,
rates of insulin-stimulated glucose uptake were not
different between the Con and HF-Lep animals. Glu-
cose uptake in the hindlimbs of the HF-Lep animals
was greater than that of the HF-FR animals, and
HF-FR animals had rates of glucose uptake that were
greater than the HF animals.
Rates of glucose transport were determined in the
Sol, Plant, WG, and RG under submaximal insulin-
stimulated conditions using the glucose analog 3-MG
(Fig. 5). 3-MG is carried by the glucose transporter but
is not phosphorylated, which results in its intracellular
accumulation representing the glucose transport pro-
cess independent of intracellular disposal. The rates of
3-MG transport in the Sol, Plant, and RG were signif-
icantly reduced in the HF animals compared with both
the Con and HF-Lep animals. Similarly, rates of 3-MG
transport in the Sol, Plant, and RG of the HF-FR group
were reduced compared with Con and HF-Lep animals.
However, no difference in rates of 3-MG transport in
the Sol, Plant, and RG existed between the HF and
HF-FR groups. Rates of 3-MG transport in the WG
were similar among all experimental groups.
Total GLUT-4 protein concentrations in the Sol,
Plant, and RG (Fig. 6) and quadricep (Fig. 7) were
signiﬁcantly greater in the Con and HF-Lep animals
compared with either the HF or HF-FR groups. No
difference in GLUT-4 protein concentration existed in
the Sol, Plant, and RG between Con and HF-Lep or HF
and HF-FR animals (Fig. 6). GLUT-4 protein concen-
Fig. 2. Serum glucose and insulin areas under the curve (AUCs)
after intravenous injection of glucose (A and B; 0–25 min) or tolbu-
tamide (C; 0–60 min) in Con (n 5 10), HF (n 5 11), high-fat diet
and leptin-treated (HF-Lep, n 5 12), or high-fat diet and food-
restricted (HF-FR, n 5 10) rats. Values are means 6 SE. *Signiﬁ-
cantly different from Con (P , 0.05). †Signiﬁcantly different from
HF (P , 0.05).
E135 SKELETAL MUSCLE INSULIN RESISTANCE AND LEPTINtration in the WG was similar among all experimental
groups (Fig. 6).
Insulin-stimulated plasma membrane GLUT-4 pro-
tein concentration was similar in the Con and HF-Lep
animals and was signiﬁcantly greater compared with
the HF group (Fig. 7). Protein concentration (mg/g wet
wt) of the plasma membrane fractions was similar
across the three treatment groups (Con: 0.57 6 0.03;
HF-Lep: 0.56 6 0.09; HF: 0.55 6 0.05). Assessment of
59-nucleotidase activity (mmolzmin
21zmg protein
21)i n -
dicated that the plasma membrane fractions were pu-
riﬁed compared with the crude homogenate (Con:
52.6 6 1.4 vs. 147.2 6 9.8; HF-Lep: 42.0 6 3.9 vs.
172.9 6 6.6; HF: 37.4 6 1.4 vs. 167.7 6 9.1).
After the 12-day treatment period, muscle glycogen
concentration was similar in the Plant, RG, and WG
among all experimental animals in perfusion group 1
(Table 4). In contrast, glycogen concentration in the Sol
of the Con group was signiﬁcantly greater compared
with HF-Lep, HF, and HF-FR animals. The glycogen
concentration in the Sol of the HF-FR animals was also
greater compared with the HF-Lep animals. Intramus-
cular triglyceride (IMTG) content was assessed in the
quadriceps of animals in perfusion group 2 (Table 4). A
3-mo high-fat diet signiﬁcantly increased intramuscu-
lar triglyceride content as evidenced in the HF group
compared with Con. Of interest, a 12-day leptin treat-
ment period signiﬁcantly reduced intramuscular tri-
glyceride levels such that the intramuscular triglycer-
ide of the Con and HF-Lep animals was similar.
Skeletal muscle enzyme activity data are shown in
Table 5. Hexokinase activity was similar among all
experimental groups and muscles except in the Sol.
Hexokinase activity in the Sol of the Con group was
signiﬁcantly greater compared with HF and HF-FR
animals. Citrate synthase activity was similar across
all experimental groups and skeletal muscles assessed
(Table 5). b-OAC activity was similar in the Sol and RG
of all experimental groups (Table 5). However, b-OAC
activity was signiﬁcantly elevated in the Plant and WG
of the HF-Lep, HF, and HF-FR groups compared with
Con animals.
DISCUSSION
Chronic leptin administration has been reported to
increase whole body glucose clearance, insulin-stimu-
lated skeletal muscle glucose uptake, and 3-MG trans-
Fig. 3. Glucose infusion rates during
hyperinsulinemic (4 mUzkg
21zmin
21
begun at time 0)-euglycemic clamp of
HF-FR (n 5 6) or HF-Lep (n 5 5) rats.
Values are means 6 SE. There was a
signiﬁcant effect of time (F 5 89.560,
P , 0.0001) and a signiﬁcant interac-
tion of time and treatment (F 5 1.808,
P , 0.05), whereas the main effect for
treatment approached signiﬁcance
(F 5 3.885, P 5 0.08).
Table 3. Body, muscle, and epididymal fat pad mass of animals in hindlimb perfusion group 1
Con (n 5 7) HF-Lep (n 5 7) HF (n 5 7) HF-FR (n 5 7)
Body mass, g
Treatment day 0 605621 764630* 761628* 764632*
Treatment day 12 613622 740632*‡ 762634* 747625*‡
Muscle mass, mg
Soleus 222.3610.3 276.1614.1* 254.569.5 247.1615.9
Plantaris 514.1616.0 583.0616.4* 591.0623.5* 532.0619.5†
Epididymal fat pad mass, g 14.161.3 22.762.1* 26.462.9* 24.461.4*
Values are means 6 SE; n, no. of animals. *Signiﬁcantly different from Con (P , 0.05). †Signiﬁcantly different from HF (P , 0.05).
‡Signiﬁcantly different from day 0 (P , 0.05).
E136 SKELETAL MUSCLE INSULIN RESISTANCE AND LEPTINport in non-insulin-resistant rats (3, 44, 60). However,
little information has been presented to date that has
evaluated the effect of chronic leptin administration in
glucose-intolerant rodents. In this investigation, we
provided male Wistar rats a high-fat diet before leptin
treatment as this feeding regimen has previously been
shown to induce skeletal muscle insulin resistance in
rats (48, 49). This diet was effective in inducing an
insulin-resistant state as it was observed that glucose
tolerance was signiﬁcantly impaired in high-fat-fed
animals (Fig. 1).
Our initial inquiry was to determine if chronic leptin
administration improved whole body glucose tolerance
in the high-fat-diet-induced insulin-resistant rats (Fig.
2). To assess these effects, we subjected animals to an
intravenous glucose tolerance test. Glucose AUC in the
HF-Lep animals were similar to those of the Con ani-
mals and were signiﬁcantly reduced compared with the
Fig. 4. Glucose uptake in hindlimbs of
Con, HF-Lep, HF, and HF-FR rats dur-
ing perfusion with 8 mM glucose and a
submaximal (500 mU/ml) insulin con-
centration; n 5 7/group. Values are
means 6 SE. *Signiﬁcantly different
from Con (P , 0.05). †Signiﬁcantly dif-
ferent from HF-Lep (P , 0.05). #Sig-
niﬁcantly different from HF (P , 0.05).
Fig. 5. 3-O-methylglucose (3-MG) trans-
port in the presence of 500 mU/ml insu-
lin in hindlimb muscles of Con, HF-Lep,
HF, and HF-FR rats; n 5 7/group. Sol,
soleus; Plant, plantaris; WG, white gas-
trocnemius; RG, red gastrocnemius.
Values are means 6 SE. *Signiﬁcantly
different from Con (P , 0.05). †Signif-
icantly different from HF-Lep (P ,
0.05).
E137 SKELETAL MUSCLE INSULIN RESISTANCE AND LEPTINHF animals. Of particular interest, the decreased glu-
cose AUC in the HF-Lep animals occurred with insulin
AUC being slightly lowered. It has been reported that
chronic leptin administration inhibits insulin secretion
from isolated islets (35) and perfused rat pancreas (18).
To further characterize the effects of chronic leptin
administration on pancreatic function, we subjected
animals to an intravenous tolbutamide tolerance test.
Tolbutamide binds to the sulfonylurea receptor in the
b-cells of the pancreas, which blocks the KATP chan-
nels, leading to an increased intracellular Ca
21 concen-
tration and increased insulin secretion (32). Unlike the
isolated islet or perfused pancreas studies, we did not
ﬁnd a difference in tolbutamide-stimulated insulin se-
cretion across treatment groups. These observations
suggest that improvements in whole body glucose tol-
erance after chronic leptin treatment result from
changes in insulin action, as opposed to alterations in
pancreatic insulin secretion. This contention is further
supported by our observation that insulin-mediated
glucose clearance was enhanced in leptin-treated ani-
mals during a hyperinsulinemic-euglycemic clamp
(Fig. 3). Although these observations have not been
reported previously in insulin-resistant animals, they
are consistent with those investigations that have ad-
ministered leptin to non-insulin-resistant animals and
subsequently found improvements in whole body insu-
lin sensitivity and glucose clearance rates (2, 3, 43).
As over 80% of a glucose load is disposed of by
skeletal muscle (14), it was determined if alterations in
skeletal muscle might account for the suppressed
whole body glucose disposal rates in response to a
high-fat diet. Rates of insulin-stimulated skeletal mus-
cle glucose uptake (Fig. 4) and 3-MG transport (Fig. 5)
were reduced signiﬁcantly in the HF and HF-FR ani-
mals. This observation is consistent with Wilkes et al.
(58), Hansen et al. (22), and Buettner et al. (8) who
reported that a high-fat diet reduces insulin-stimu-
Fig. 6. GLUT-4 protein concentration,
expressed as a percentage of a heart
standard, in skeletal muscles from rats
that were divided among 1 of 4 groups:
Con, HF-Lep, HF, and HF-FR; n 5
7/group. Values are means 6 SE. *Sig-
niﬁcantly different from Con (P ,
0.05). †Signiﬁcantly different from HF-
Lep (P , 0.05).
Fig. 7. Total and insulin-stimulated
plasma membrane (PM) GLUT-4 pro-
tein concentration, expressed as a per-
centage of a heart standard, in quadri-
cep muscles from rats that were divided
among 1 of 3 groups (Con, HF-Lep, and
HF) and subjected to hindlimb perfu-
sion; n 5 8/group. Values are means 6
SE. *Signiﬁcantly different from Con
(P , 0.05). †Signiﬁcantly different
from HF-Lep (P , 0.05).
E138 SKELETAL MUSCLE INSULIN RESISTANCE AND LEPTINlated 3-MG transport (22, 58) and 2-deoxyglucose up-
take (8, 22) in rodent skeletal muscle. The key obser-
vation in the present investigation was that 12 days of
leptin administration completely reversed high-fat-di-
et-induced skeletal muscle insulin resistance, resulting
in similar rates of insulin-stimulated skeletal muscle
glucose uptake and 3-MG transport in Con and HF-Lep
animals.
The high-fat diet appeared to induce skeletal muscle
insulin resistance by suppressing the expression of the
glucose transporter GLUT-4 (Fig. 6). This observation
is similar to that of Kahn and Pedersen (26), who
reported total GLUT-4 protein concentration is re-
duced in quadricep muscle of Sprague-Dawley rats
subjected to a high-fat diet. Hansen et al. (22) also
investigated the effects of a high-fat diet on GLUT-4
protein in rodent skeletal muscle. Although these in-
vestigators, did not evaluate total skeletal muscle
GLUT-4 protein concentration, they did ﬁnd that a
high-fat diet reduced insulin-stimulated cell surface
GLUT-4 protein concentration. In agreement with
Hansen et al., we observed insulin-stimulated translo-
cation of glucose transporters to the plasma membrane
to be reduced in the HF animals (Fig. 7).
Most striking, we found that 12 days of leptin ad-
ministration completely normalized total skeletal mus-
cle (Figs. 6 and 7) and insulin-stimulated plasma mem-
brane GLUT-4 protein concentrations (Fig. 7) in
animals fed a high-fat diet. When rates of 3-MG trans-
port (Fig. 5) and skeletal muscle GLUT-4 protein con-
centration (Fig. 6) were compared, the alterations in
total skeletal muscle GLUT-4 protein concentration
could virtually account for either the reduction or ele-
vation in rates of insulin-stimulated 3-MG transport.
This observation is consistent with previous reports
that have shown insulin-stimulated skeletal muscle
3-MG glucose transport rates to be related to the total
GLUT-4 protein concentration (1, 7, 23, 28). Further-
more, several investigations have demonstrated that
the total pool of skeletal muscle GLUT-4 protein is
associated with the amount of GLUT-4 translocated to
the plasma membrane in response to insulin (15, 40).
Therefore, it is reasonable to suggest that insulin-
stimulated skeletal muscle 3-MG transport was im-
proved in the HF-Lep animals due to leptin treatment
normalizing the total GLUT-4 protein concentration,
which in turn resulted in a greater number of glucose
transporters being translocated to the plasma mem-
brane in response to insulin. However, chronic leptin
administration did not appear to affect 3-MG transport
or GLUT-4 protein concentration in the WG (a type IIb
Table 4. Glycogen and intramuscular triglyceride concentration in selected muscles from male Wistar rats
after the 12-day treatment period
Con HF-Lep HF HF-FR
Glycogen (glucosyl units), mmol/g wet wt
n 77 7 7
Soleus 38.8361.1 27.4762.1* 27.8862.0* 33.1162.0*†
Plantaris 44.8163.7 34.2364.1 36.6064.0 35.6563.4
WG 50.8362.9 44.7564.0 46.5261.9 41.6363.6
RG 42.0462.7 40.8463.8 39.0063.6 45.9561.3
Intramuscular triglycerides, mg/g wet wt
n 88 8 N D
Quadricep 1.9960.19 4.0761.19 6.4960.50*†
Values are means 6 SE; n, no. of animals. WG, white gastrocnemius; RG, red gastrocnemius. ND, not determined as perfusion group 2 did
not have a HF-FR group (see METHODS). *Signiﬁcantly different from Con (P , 0.05). †Signiﬁcantly different from HF-Lep (P , 0.05).
Table 5. Enzymatic activities in selected muscles from male Wistar rats after the 12-day treatment period
Con (n 5 7)
HF-Lep
(n 5 7) HF (n 5 7)
HF-FR
(n 5 7)
Hexokinase activity, mmolzg
21zmin
21
Soleus 3.0160.1 2.7460.2 2.5060.1* 2.6360.1*
Plantaris 2.1060.1 2.1360.1 2.2260.1 2.0660.2
WG 1.0460.06 0.9660.06 0.9860.04 0.9360.05
RG 2.1060.1 1.9660.1 1.8260.1 1.9560.1
Citrate synthase activity, mmolzg
21zmin
21
Soleus 47.4762.0 47.1961.4 46.9462.3 45.2463.1
Plantaris 50.6562.1 52.7961.8 50.0861.3 54.6562.3
WG 23.2662.3 27.3462.9 26.7161.7 25.6362.8
RG 56.4662.6 58.3063.0 57.6262.2 56.9762.0
b-OAC activity, mmolzg
21zmin
21
Soleus 58.6761.4 59.4961.6 63.9762.3 61.6562.8
Plantaris 27.3262.0 37.6962.1* 35.3062.4* 37.4162.8*
WG 8.0660.4 9.9160.7* 9.8460.6* 10.3760.7*
RG 31.0162.0 33.8262.0 34.3762.4 36.5263.1
Values are means 6 SE; n, no. of animals. b-OAC, b-hydroxyacetyl-CoA dehydrogenase. *Signiﬁcantly different from Con (P , 0.05).
E139 SKELETAL MUSCLE INSULIN RESISTANCE AND LEPTINﬁber), which suggests that leptin does not affect the
glucose transport pathway in glycolytic muscle ﬁbers.
While plausible to suggest that chronic leptin admin-
istration improves insulin-stimulated glucose uptake
and transport due to reductions in visceral fat concen-
tration, it has been reported recently that the effect of
leptin administration on peripheral insulin action can-
not be explained solely by decreases in visceral fat
deposition (2). Therefore, the possibility exists that
secondary effects in response to leptin treatment may
have accounted for these effects. Leptin administration
alters skeletal muscle metabolism by shifting the mus-
cle from lipid storage to fat oxidation (33). Because a
reduction in skeletal muscle triglyceride levels im-
proves whole body glucose tolerance (30), leptin may
improve insulin-stimulated glucose uptake and trans-
port, in part, by altering the intramuscular triglyceride
concentration (8). This possibility is consistent with
our ﬁnding that leptin administration for 12 days re-
duced intramuscular triglyceride levels in animals that
had been subjected to 3 mo of a high-fat diet (Table 4).
Chronic leptin treatment may also improve an insulin-
resistant state by attenuating the effects of an elevated
blood tumor necrosis factor-a (TNF-a) level. TNF-a is
secreted from highly active adipocytes in the abdomi-
nal region, and serum TNF-a levels have been reported
to be elevated in obese, type II diabetics (27). An excess
of TNF-a attenuates in vitro expression of GLUT-4
(46), inhibits insulin receptor tyrosine kinase activity
(24), and impairs insulin-stimulated glucose uptake in
C2C12 muscle cells (16). Of particular relevance, exog-
enous leptin administration has been reported to at-
tenuate the effects of elevated TNF-a levels (50).
Alternatively, the improvements in insulin-stimu-
lated glucose uptake and transport may be due to
leptin exerting a primary effect in the skeletal muscle.
Skeletal muscle expresses both long and short isoforms
of the leptin receptor (20, 51). The leptin receptor is a
member of the gp130 family of cytokine receptors,
which stimulate gene transcription via activation of
cytosolic STAT proteins (5). Both leptin receptor iso-
forms have signal transduction capabilities (20, 34).
Although the activation and effect of these signals in
skeletal muscle in response to chronic leptin adminis-
tration are unknown, it is possible that chronic leptin
treatment may improve insulin-stimulated glucose
transport in skeletal muscle by initiating increases in
GLUT-4 protein concentration.
Rates of skeletal muscle glucose uptake and trans-
port can be elevated in response to increased whole
body energy expenditure (21, 37) and/or decreased ca-
loric intake (11, 60), both of which could result in a
reduced muscle glycogen concentration. A reduction in
muscle glycogen will facilitate insulin-stimulated glu-
cose uptake and transport (19). However, muscle gly-
cogen concentration was similar across all treatment
groups, with the exception of the Sol (Table 4). There-
fore, muscle glycogen levels cannot completely account
for differences in rates of glucose uptake and transport
that were observed among the experimental groups
(Figs. 4 and 5). This ﬁnding is in agreement with Dean
et al. (13) who reported that caloric restriction does not
reduce skeletal muscle glycogen levels or directly in-
ﬂuence rates of insulin-stimulated glucose transport.
Cartee and associates (10, 13) have reported that ca-
loric intake can inﬂuence insulin action and membrane
permeability to glucose in skeletal muscle. Although
3-MG transport may have been elevated in the HF-Lep
animals due to caloric restriction, the HF-Lep and
HF-FR animals consumed a similar amount of food
throughout the experimental period. Thus any differ-
ences in insulin-stimulated glucose uptake and trans-
port that existed between the HF-Lep and HF-FR an-
imals can presumably be attributed to the effects of
chronic leptin treatment.
In summary, we found that a high-fat diet reduced
glucose tolerance and insulin-stimulated skeletal mus-
cle glucose disposal, glucose uptake, and 3-MG trans-
port. Insulin resistance in the skeletal muscles of the
animals subjected to the high-fat diet appeared to be
due to a reduced GLUT-4 protein concentration. Ani-
mals subjected to a high-fat diet and subsequently
treated with leptin exhibited rates of insulin-stimu-
lated glucose uptake and 3-MG transport that were
identical to Con animals. It appeared that this im-
provement was due to leptin treatment reversing a
high-fat diet-induced skeletal muscle insulin resis-
tance, at least in part, by normalizing the total skeletal
muscle GLUT-4 protein concentration.
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